Page Title
Drug Development Pipeline
ViaNautis Bio
Status
Pre-clinicalTherapeutic Approach
Genetic Therapy
This program is developing a new method to deliver genetic therapies to the lungs of people with CF. polyNaut® is a non-viral genetic therapy delivery mechanism that aims to reach targeted cells in the CF lungs and carry large genetic therapy payloads — two major challenges in delivering a CF genetic therapy. This approach may also allow for redosing of the genetic therapy, a useful option if the therapy’s effects are not permanent.
Status
Laboratory studies to develop and test this technology are underway.
Sponsor
This program is sponsored by ViaNautis Bio and partially funded by the Cystic Fibrosis Foundation.

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More